Aortic & peripheral vascular disease
Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis
Pooled resultResult — go to the resultPooled hazard ratio .75 95% CI .56-.93Authors' conclusion
This updated meta-analysis of RCTs demonstrated a substantial reduction in MACE, MI, ischaemic stroke, and recurrent coronary revascularization with colchicine compared with placebo.
Study context
- Population
- Patients with clinically manifest vascular disease, ≥12-month follow-up
- Participants
- 21,800 patients6 randomized controlled trials (RCTs)
- Comparison
- Colchicine vs placebo
- Colchicinen = 10,871
- Placebon = 10,929reference
- Outcome
- Major adverse cardiovascular events (MACE):
- CV mortality
- MI
- Ischaemic stroke
- Urgent coronary revascularization
- Follow-up
- 12-34 months
Methodological detailsrandom effects model
- Random effects model
Pooled result
As reported in the abstract
Pooled hazard ratio
.75
95% CI .56-.93
Colchicinevs Placebo
pooled HR .75 (95% CI .56-.93)
Further pooled results
MI, ischaemic stroke, urgent coronary revascularization
- Reduced with colchicine
- P < 0.05 for all
Safety
Safety outcomes, including non-CV deaths
- No differences detected for safety outcomes
- P > 0.05 for all
- Non-CV deaths, RR
- 1.08 (95% CI .76-1.54)
Original publication
Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis. Eur Heart J. Published 2 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →